Consonance Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Consonance Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-409,301	Closed	-$31.8M	–	25
2021 Q2	$31.8M	Buy	+409,301	New	+$31M	3.83%	8
2020 Q3	–	Sell	-425,716	Closed	-$68.3M	–	36
2020 Q2	$68.3M	Sell	425,716 -397,449	-48%	-$54.1M	4.09%	14
2020 Q1	$80.5M	Buy	823,165 +467,020	+131%	+$53.4M	6%	5
2019 Q4	$46M	Buy	356,145 +344,145	+2,868%	+$34.7M	2.8%	14
2019 Q3	$904K	Buy	+12,000	New	+$1.42M	0.09%	27

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Consonance Capital Management's SRPT Position: Q3 2021 in Review

Consonance Capital Management sold out of Sarepta Therapeutics (SRPT) in Q3 2021, closing a stake of 409,301 shares — an estimated $31.8M sold.

Consonance Capital Management first reported a position in SRPT in Q3 2019 and held it in 5 quarters. The position peaked at $80.5M in Q1 2020. 306 funds tracked by Wall St. Rank hold SRPT as of Q3 2021.

Consonance Capital Management reported no remaining Sarepta Therapeutics position as of Q3 2021 after selling out during the quarter.
Consonance Capital Management sold 409,301 Sarepta Therapeutics shares in Q3 2021, an estimated $31.8M.
Consonance Capital Management first reported a position in Sarepta Therapeutics in Q3 2019 and held it in 5 quarters.
Consonance Capital Management's Sarepta Therapeutics position peaked at $80.5M in Q1 2020.
306 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2021.

Based on Consonance Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.